Back to top

Analyst Blog

Sucampo Pharmaceuticals, Inc. (SCMP - Snapshot Report) recently received a milestone payment of $10 million from Takeda Pharmaceutical Company Limited (TKPYY). The payment was in accordance with a licensing and collaboration agreement between the two companies. The milestone payment was earned on the commercial launch of Amitiza in the US for the treatment of opioid-induced constipation (OIC) in adults with chronic, non-cancer pain.

Sucampo and Takeda’s association goes back to Oct 2004 when the companies collaborated for the development and commercialization of Amitiza in the US and Canada. According to the agreement, Sucampo stands to receive up to $50 million toward development costs for each additional indication and $20 million for each additional formulation.

All costs will be shared equally thereafter. Takeda has paid a total of $104.7 million toward research and development reimbursement as of Dec 31, 2012.

Amitiza was approved by the US Food and Drug Administration (FDA) in 2006 for chronic idiopathic constipation (CIC) in adults. Furthermore, it gained FDA approval in 2008 for irritable bowel syndrome with constipation (IBS-C) in adult women.

Amitiza is approved for CIC in Switzerland as well as the UK and for chronic constipation (CC) in Japan. Sucampo reported $64.9 million US net sales of Amitiza in the first quarter of 2013. Amitiza currently holds the status of being the only oral approved therapy for OIC in adult patients with chronic, non-cancer pain.

Several companies like Salix Pharmaceutical Ltd./Progenics Pharmaceuticals, Inc. (SLXP - Analyst Report)/(PGNX - Snapshot Report) are developing candidates for OIC in patients with chronic pain.

Sucampo currently carries a Zacks Rank #3 (Hold). Meanwhile, Salix Pharma looks well-positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%